IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Pharmaceutical Manufacturing in China Industry Data and Analysis
Revenue for the Pharmaceutical Manufacturing industry is expected to decrease at an annualized 0.2% over the five years through 2025, to total $183.2 billion, up 2.8% from 2024. The COVID-19 outbreak contributed to growth in domestic demand for medicine and medical supplies, benefiting the development of the Pharmaceutical Manufacturing industry. The industry's profitability has decreased from 13.6% of industry revenue in 2020 to 13.1% in 2025. An estimated 1,616 industry enterprises operate in 2025, employing about 716,920 people, with a total wage cost of $12.5 billion.Hospitals are currently the main distribution channel for the medicine produced by the industry. However, upcoming healthcare reforms are anticipated to enable drugstores to become the major distribution channel in the near future. In the past, many consumers could not afford to purchase medicine or see a doctor.The Government in China will continue to implement policies to restrict and decrease medicine prices, and accelerate urban and rural residents' work insurance relating to a serious illness, improve rural residents' insurance demand, and allow more consumers to purchase medicine when required. As a result, industry revenue is forecast to increase at an annualized 3.5% over the five years through 2030, total $217.6 billion.Intensified domestic market competition drives domestic enterprises to continue developing overseas market over the next five years. In addition, lower price advantages and increasing research and development content of products also promote growing demand for China's pharmaceutical products. Industry exports are forecast to increase at an annualized 9.9% over the five years through 2030.Though domestic demand for basic and high-quality pharmaceutical products is anticipated to grow substantially, imports will increase slowly due to domestic substitution. Many patents for pharmaceutical and medicine products will expire over the next five years. Instead of importing these pharmaceuticals, domestic companies will be able to manufacture them at a lower cost and sell them at a lower price in the domestic market.
Access this data your way
The Pharmaceutical Manufacturing in China Industry analysis is available in multiple formats to fit seamlessly into your workflow.
API Data Delivery
Feed trusted, human-driven industry intelligence straight into your platform.
Integrations
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
What's included in this industry analysis
IBISWorld's research coverage on the Pharmaceutical Manufacturing industry in China includes market sizing, forecasting, data and analysis from 2015-2030. The most recent publication was released July 2025.
About this industry
What's this industry report about?
The Pharmaceutical Manufacturing industry in China operates under the industry code 2720. The industry primarily manufactures chemical medicinal and pharmaceutical products in various formats, including ampoules, tablets, capsules, vials, ointments, powders, solutions, suspensions and radioactive medicine. These products are then sold through pharmacies or used in hospitals. Biological and veterinary medicine products are not included in the industry. Related terms covered in the Pharmaceutical Manufacturing industry in China include over-the-counter (otc), microecology and good manufacturing practice (gmp).
What's included in this industry?
Products and services covered in Pharmaceutical Manufacturing industry in China include Anti-infective drugs, Anti-tumor and cancer drugs and Nervous system drugs.
What companies are included in this industry?
Companies covered in the Pharmaceutical Manufacturing industry in China include Jiangsu Hengrui Pharmaceuticals Co., Ltd., Sino Biopharmaceutical Limited and Shanghai Pharmaceuticals Holding Co., Ltd.
Performance
What's included in the Performance chapter?
The Performance chapter covers detailed analysis, datasets, detailed current performance, sources of volatility and an outlook with forecasts for the Pharmaceutical Manufacturing industry in China.
Questions answered in this chapter include what's driving current industry performance, what influences industry volatility, how do successful businesses overcome volatility, what's driving the industry outlook. This analysis is supported with data and statistics on industry revenues, costs, profits, businesses and employees.
Products & Markets
What's included in the Products and Markets chapter?
The Products and Markets chapter covers detailed product and service segmentation, analysis of major markets and international trade data for the for the Pharmaceutical Manufacturing industry in China.
Questions answered in this chapter include how are the industry's products and services performing, what are innovations in industry products and services, what products or services do successful businesses offer and what's influencing demand from the industry's markets. This includes data and statistics on industry revenues by product and service segmentation and major markets.
Geographic Breakdown
What's included in the Geographic Breakdown chapter?
The Geographic Breakdown chapter covers detailed analysis and datasets on regional performance of the Pharmaceutical Manufacturing industry in China.
Questions answered in this chapter include where are industry businesses located and how do businesses use location to their advantage. This includes data and statistics on industry revenues by location.
Competitive Forces
What's included in the Competitive Forces chapter?
The Competitive Forces chapter covers the concentration, barriers to entry and supplier and buyer profiles in the Pharmaceutical Manufacturing industry in China. This includes data and statistics on industry market share concentration, barriers to entry, substitute products and buyer & supplier power.
Questions answered in this chapter include what impacts the industry's market share concentration, how do successful businesses handle concentration, what challenges do potential industry entrants face, how can potential entrants overcome barriers to entry, what are substitutes for industry services, how do successful businesses compete with substitutes and what power do buyers and suppliers have over the industry and how do successful businesses manage buyer & supplier power.
Companies
What's included in the Companies chapter?
The Companies chapter covers Key Takeaways, Market Share and Companies in the Pharmaceutical Manufacturing industry in China. This includes data and analysis on companies operating in the industry that hold a market share greater than 5%.
Questions answered in this chapter include what companies have a meaningful market share and how each company is performing.
External Environment
What's included in the External Environment chapter?
The External Environment chapter covers Key Takeaways, External Drivers, Regulation & Policy and Assistance in the Pharmaceutical Manufacturing industry in China. This includes data and statistics on factors impacting industry revenue such as economic indicators, regulation, policy and assistance programs.
Questions answered in this chapter include what demographic and macroeconomic factors impact the industry, what regulations impact the industry, what assistance is available to this industry.
Financial Benchmarks
What's included in the Financial Benchmarks chapter?
The Financial Benchmarks chapter covers Key Takeaways, Cost Structure, Financial Ratios, Valuation Multiples and Key Ratios in the Pharmaceutical Manufacturing industry in China. This includes financial data and statistics on industry performance including key cost inputs, profitability, key financial ratios and enterprise value multiples.
Questions answered in this chapter include what trends impact industry costs and how financial ratios have changed overtime.
Industry Data
What's included in the Industry Data chapter?
The Industry Data chapter includes 10 years of historical data with 5 years of forecast data covering statistics like revenue, industry value add, establishments, enterprises, employment and wages in the Pharmaceutical Manufacturing industry in China.
Trusted by industry professionals
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
Frequently Asked Questions
What is the market size of the Pharmaceutical Manufacturing industry in China in 2026?
The market size of the Pharmaceutical Manufacturing industry in China is $183.2bn in 2026.
How many businesses are there in the Pharmaceutical Manufacturing industry in China in 2025?
There are 1,616 businesses in the Pharmaceutical Manufacturing industry in China, which has grown at a CAGR of 0.2 % between 2020 and 2025.
How may import tariffs affect the Pharmaceutical Manufacturing industry in China?
The Pharmaceutical Manufacturing industry in China is unlikely to be materially impacted by import tariffs with imports accounting for a low share of industry revenue.
How may export tariffs affect the Pharmaceutical Manufacturing industry in China?
The Pharmaceutical Manufacturing industry in China is unlikely to be materially impacted by export tariffs with exports accounting for a low share of industry revenue.
Has the Pharmaceutical Manufacturing industry in China grown or declined over the past 5 years?
The market size of the Pharmaceutical Manufacturing industry in China has been declining at a CAGR of 0.2 % between 2020 and 2025.
What is the forecast growth of the Pharmaceutical Manufacturing industry in China over the next 5 years?
Over the next five years, the Pharmaceutical Manufacturing industry in China is expected to grow.
What are the biggest companies in the Pharmaceutical Manufacturing industry in China?
The biggest companies operating in the Pharmaceutical Manufacturing industry in China are Jiangsu Hengrui Pharmaceuticals Co., Ltd., Sino Biopharmaceutical Limited and Shanghai Pharmaceuticals Holding Co., Ltd.
What does the Pharmaceutical Manufacturing industry in China include?
Anti-infective drugs and Anti-tumor and cancer drugs are part of the Pharmaceutical Manufacturing industry in China.
Which companies have the highest market share in the Pharmaceutical Manufacturing industry in China?
The company holding the most market share in the Pharmaceutical Manufacturing industry in China is Jiangsu Hengrui Pharmaceuticals Co., Ltd..
How competitive is the Pharmaceutical Manufacturing industry in China?
The level of competition is high and increasing in the Pharmaceutical Manufacturing industry in China.
Cut through the noise with intelligence you can trust
